Fundraising FoxAmplyx
14 known investors
Find your way into Amplyx
Sign up to see every warm intro you have to Amplyx
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Amplyx team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Developing a new class of antifungal medicine to overcome limitations of current therapies.
Investors · 14
How we know: Golden Seeds's portfolio page · Not right? Tell us
How we know: Keiretsu Forum's portfolio page · Not right? Tell us
How we know: Pappas Capital's portfolio page · Not right? Tell us
How we know: RiverVest Venture Partners's portfolio page · biospace.com · Not right? Tell us
How we know: Sofinnova Ventures's portfolio page · prnewswire.com · the VCSheet dataset · Not right? Tell us
How we know: biospace.com · Not right? Tell us
How we know: biospace.com · Not right? Tell us
Also in the syndicate · 3
Funding
SEC filings, press & company announcements- Undisclosed amountSeries C extensionMay 2020
Sofinnova Investment (lead), 3x5 Partners, Adage Capital Management, Arix Bioscience, BioMed Ventures, Lundbeckfonden Ventures, New Enterprise Associates, Pappas Capital, Pfizer, RiverVest Venture Partners
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Non-dilutive funding · 13 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2015 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2014 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2014 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $696.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $599.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $697.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $580.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $558.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $301K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2011 | $300K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Amplyx do?
- Developing a new class of antifungal medicine to overcome limitations of current therapies.
- Who are Amplyx's investors?
- Amplyx's investors include BioBrit, Golden Seeds, Keiretsu Forum, Pappas Capital, RiverVest Venture Partners, Sofinnova Ventures, 3x5 Partners, Arix Bioscience and 3 more.